Anticancer activity of FTY720: Phosphorylated FTY720 inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase D

Cancer Letters

Volumn 266, Issue 2, 2008, Pages 203-208

  van Meeteren, Laurens A ^a   Brinkmann, Volker ^b   Saulnier Blache, Jean Sébastien ^c   Lynch, Kevin R ^d   Moolenaar, Wouter H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b NOVARTIS PHARMA AG   (Switzerland)

^c INSERM   (France)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Autotaxin; FTY720; Lysophosphatidic acid; Tumor progression

Indexed keywords

AUTOTAXIN; FINGOLIMOD; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHOLIPASE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SPECIFICITY; EMBRYO; FEMALE; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LYSOPHOSPHOLIPIDS; MICE; MICE, INBRED C57BL; MULTIENZYME COMPLEXES; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHODIESTERASE I; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC ACID ESTERS; PHOSPHORIC DIESTER HYDROLASES; PYROPHOSPHATASES; SPHINGOSINE;

MUS;

EID: 45049086146     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.02.052     Document Type: Article

References (30)

1. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol. Ther. 115 (2007) 84-105
2. Mandala S., Hajdu R., Bergstrom J., Quackenbush E., Xie J., Milligan J., Thornton R., Shei G.J., Card D., Keohane C., Rosenbach M., Hale J., Lynch C.L., Rupprecht K., Parsons W., and Rosen H. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296 (2002) 346-349
3. Brinkmann V., Davis M.D., Heise C.E., Albert R., Cottens S., Hof R., Bruns C., Prieschl E., Baumruker T., Hiestand P., Foster C.A., Zollinger M., and Lynch K.R. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 277 (2002) 21453-21457
4. Oo M.L., Thangada S., Wu M.T., Liu C.H., Macdonald T.L., Lynch K.R., Lin C.Y., and Hla T. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J. Biol. Chem. 282 (2007) 9082-9089
5. Schwab S.R., and Cyster J.G. Finding a way out: lymphocyte egress from lymphoid organs. Nat. Immunol. 8 (2007) 1295-1301
6. Azuma H., Takahara S., Ichimaru N., Wang J.D., Itoh Y., Otsuki Y., Morimoto J., Fukui R., Hoshiga M., Ishihara T., Nonomura N., Suzuki S., Okuyama A., and Katsuoka Y. Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res. 62 (2002) 1410-1419
7. Chua C.W., Lee D.T., Ling M.T., Zhou C., Man K., Ho J., Chan F.L., Wang X., and Wong Y.C. FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer. Int. J. Cancer 117 (2005) 1039-1048
8. Lee T.K., Man K., Ho J.W., Wang X.H., Poon R.T., Xu Y., Ng K.T., Chu A.C., Sun C.K., Ng I.O., Sun H.C., Tang Z.Y., Xu R., and Fan S.T. FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma. Clin. Cancer Res. 11 (2005) 8458-8466
9. Schmid G., Guba M., Ischenko I., Papyan A., Joka M., Schrepfer S., Bruns C.J., Jauch K.W., Heeschen C., and Graeb C. The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1. J. Cell Biochem. 101 (2007) 259-270
10. LaMontagne K., Littlewood-Evans A., Schnell C., O' Reilly T., Wyder L., Sanchez T., Probst B., Butler J., Wood A., Liau G., Billy E., Theuer A., Hla T., and Wood J. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res. 66 (2006) 221-231
11. Neviani P., Santhanam R., Oaks J.J., Eiring A.M., Notari M., Blaser B.W., Liu S., Trotta R., Muthusamy N., Gambacorti-Passerini C., Druker B.J., Cortes J., Marcucci G., Chen C.S., Verrills N.M., Roy D.C., Caligiuri M.A., Bloomfield C.D., Byrd J.C., and Perrotti D. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J. Clin. Invest. 117 (2007) 2408-2421
12. Liu Q., Zhao X., Frissora F., Ma Y., Santhanam R., Jarjoura D., Lehman A., Perrotti D., Chen C.S., Dalton J.T., Muthusamy N., and Byrd J.C. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood 111 (2008) 275-284
13. van Meeteren L.A., Ruurs P., Christodoulou E., Goding J.W., Takakusa H., Kikuchi K., Perrakis A., Nagano T., and Moolenaar W.H. Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate. J. Biol. Chem. 280 (2005) 21155-21161
14. Stefan C., Jansen S., and Bollen M. NPP-type ectophosphodiesterases: unity in diversity. Trends Biochem. Sci. 30 (2005) 542-550
15. Umezu-Goto M., Kishi Y., Taira A., Hama K., Dohmae N., Takio K., Yamori T., Mills G.B., Inoue K., Aoki J., and Arai H. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J. Cell Biol. 158 (2002) 227-233
16. van Meeteren L.A., and Moolenaar W.H. Regulation and biological activities of the autotaxin-LPA axis. Prog. Lipid Res. 46 (2007) 145-160
17. Moolenaar W.H., van Meeteren L.A., and Giepmans B.N. The ins and outs of lysophosphatidic acid signaling. Bioessays 26 (2004) 870-881
18. Mills G.B., and Moolenaar W.H. The emerging role of lysophosphatidic acid in cancer. Nat. Rev. Cancer 3 (2003) 582-591
19. Ishii I., Fukushima N., Ye X., and Chun J. Lysophospholipid receptors: signaling and biology. Annu. Rev. Biochem. 73 (2004) 321-354
20. Boucharaba A., Serre C.M., Gres S., Saulnier-Blache J.S., Bordet J.C., Guglielmi J., Clezardin P., and Peyruchaud O. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J. Clin. Invest. 114 (2004) 1714-1725
21. Boucharaba A., Serre C.M., Guglielmi J., Bordet J.C., Clezardin P., and Peyruchaud O. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc. Natl. Acad. Sci. USA 103 (2006) 9643-9648
22. Nam S.W., Clair T., Campo C.K., Lee H.Y., Liotta L.A., and Stracke M.L. Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene 19 (2000) 241-247
23. Nam S.W., Clair T., Kim Y.S., McMarlin A., Schiffmann E., Liotta L.A., and Stracke M.L. Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res. 61 (2001) 6938-6944
24. Baker D.L., Fujiwara Y., Pigg K.R., Tsukahara R., Kobayashi S., Murofushi H., Uchiyama A., Murakami-Murofushi K., Koh E., Bandle R.W., Byun H.S., Bittman R., Fan D., Murph M., Mills G.B., and Tigyi G. Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. J. Biol. Chem. 281 (2006) 22786-22793
25. van Meeteren L.A., Ruurs P., Stortelers C., Bouwman P., van Rooijen M.A., Pradere J.P., Pettit T.R., Wakelam M.J., Saulnier-Blache J.S., Mummery C.L., Moolenaar W.H., and Jonkers J. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol. Cell. Biol. 26 (2006) 5015-5022
26. Tanaka M., Okudaira S., Kishi Y., Ohkawa R., Iseki S., Ota M., Noji S., Yatomi Y., Aoki J., and Arai H. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J. Biol. Chem. 281 (2006) 25822-25830
27. Ferguson C.G., Bigman C.S., Richardson R.D., van Meeteren L.A., Moolenaar W.H., and Prestwich G.D. Fluorogenic phospholipid substrate to detect lysophospholipase D/autotaxin activity. Org. Lett. 8 (2006) 2023-2026
28. Saulnier-Blache J.S., Girard A., Simon M.F., Lafontan M., and Valet P. A simple and highly sensitive radioenzymatic assay for lysophosphatidic acid quantification. J. Lipid Res. 41 (2000) 1947-1951
29. Clair T., Krutzsch H.C., Liotta L.A., and Stracke M.L. Nucleotide binding to autotaxin: crosslinking of bound substrate followed by lysC digestion identifies two labeled peptides. Biochem. Biophys. Res. Commun. 236 (1997) 449-454
30. Matsuoka Y., Nagahara Y., Ikekita M., and Shinomiya T. A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br. J. Pharmacol. 138 (2003) 1303-1312